Immuneering (id:6614 IMRX)
2.10 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:25:14 PM)
Exchange closed, opens in 1 day 11 hours
-2.78 USD (-2.78%)
16.67 USD (16.67%)
-9.09 USD (-9.09%)
45.83 USD (45.83%)
-72.80 USD (-72.80%)
-89.23 USD (-89.23%)
About Immuneering
Market Capitalization 65.21M
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Headquarters (address) |
245 Main Street Cambridge 02142 MA United States |
| Phone | 617 500 8080 |
| Website | https://immuneering.com |
| Employees | 66 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | IMRX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.00 - 8.89 |
| Market Capitalization | 65.21M |
| P/E trailing | -1.12 |
| P/E forward | -1.28 |
| Price/Book | 0.679 |
| Beta | -0.400 |
| EPS | -1.97 |
| EPS United States (ID:6, base:3403) | 24.22 |